Search results
Added:
2 years ago
AHA ISC 2024 — Dr Anne Alexandrov (University of Tennessee Health Science Center, US) joins us to summarise the key findings from the Zero Degree Head Positioning in Hyperacute Large Artery Ischaemic Stroke (ZODIAC) trial (NCT03728738).ZODIAC is a prospective randomized open blinded endpoint (PROBE) clinical trial investigating head positioning in hyperacute LVO ischemic stroke treatment. It aims…
View more
Added:
10 months ago
Added:
3 weeks ago
Source:
Radcliffe CVRM
A spectrum of primary aldosteronism, indicated by a higher aldosterone-renin ratio (ARR), may contribute to an increased risk of atrial fibrillation (AF) and ischaemic stroke in older adults, according to a new cohort study analysis.¹MethodologyThis prospective cohort analysis used data from the Atherosclerosis Risk in Communities (ARIC) study. The investigation included 3,477 community-dwelling…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
Renin-independent aldosteronism is a common and often underrecognised condition. A new analysis from the Atherosclerosis Risk in Communities (ARIC) study has investigated whether this broader spectrum of aldosteronism is associated with incident cardiovascular disease (CVD) in older, community-dwelling adults.¹MethodologyThis prospective cohort analysis included 3,477 participants from the ARIC…
View more
Added:
2 months ago
Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, New York, NY, US) joins us to discuss evolving strategies for stroke management following atrial fibrillation ablation, addressing the critical question of when anticoagulation can be safely discontinued after successful ablation.Interview Questions:There's been a lot of talk about optimal anticoagulation – what's the headline? In which…
View more
Added:
2 years ago
EHRA 24 - Investigator, Dr William McIntyre (Population Health Research Institute, CA) joins us to discuss the findings from a substudy of ARTESiA (NCT01938248).ARTESiA was a randomized, parallel assignment clinical trial which aimed to assess if apixaban could reduce the risk of ischemic stroke and systemic embolism in patients with subclinical atrial fibrillation (AF) and additional risk…
View more
Added:
2 years ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of…
View more
Added:
1 year ago
Added:
11 months ago